Tariff Fears Trim 2.96% off Novo Nordisk Stock, Oral Wegovy Fuels 9.1% Jump
A sudden selloff in European markets following Goldman Sachs’s warning on U.S. tariff threats pressured Novo Nordisk shares down 2.96% on Monday. Separately, early U.S. prescriptions for its oral Wegovy exceeded expectations, driving a 9.1% share surge in the first week after its early January launch.
1. European Tariff Threats Weigh on Novo Nordisk Shares
In Monday’s trading session, Novo Nordisk shares fell by 2.96% after pan-European equities declined in response to Goldman Sachs’ warning that U.S. tariffs of 10% (rising to 25%) on imports from eight European countries could reduce GDP by up to 0.5% in the worst-case scenario. As a major exporter of diabetes and obesity treatments, Novo Nordisk faced direct pressure from investors concerned about weaker transatlantic demand and potential knock-on effects on the company’s international sales growth and profit margins.
2. Oral Wegovy Launch Spurs 9.1% Rally on Early U.S. Demand
Separately, Novo Nordisk shares jumped 9.1% following reports that oral Wegovy prescriptions in the U.S. exceeded 15,000 in the first week after its early January launch, according to pharmacy dispensing data. The rapid uptake—driven by patient preference for a non-injectable GLP-1 receptor agonist—suggests a strong commercial runway for the pill formulation. Analysts now forecast that oral Wegovy could contribute up to 5% of Novo Nordisk’s global sales by year-end, bolstering expectations for full-year revenue growth in excess of 12%.